Publications by authors named "Linda Janisch"

22Publications

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.

J Clin Pharmacol 2019 12 5;59(12):1632-1640. Epub 2019 Jul 5.

Department of Medicine, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1476DOI Listing
December 2019

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2018 08 9;82(2):309-317. Epub 2018 Jun 9.

Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3619-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739841PMC
August 2018

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Br J Cancer 2018 04 19;118(8):1042-1050. Epub 2018 Mar 19.

Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, 1400 Holcombe Boulevard, Unit 455, Faculty Center 8th Floor, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0020-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931107PMC
April 2018

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 06 13;36(16):1611-1618. Epub 2018 Feb 13.

Jason J. Luke, Jeffrey M. Lemons, Theodore G. Karrison, Sean P. Pitroda, James M. Melotek, Yuanyuan Zha, Hania A. Al-Hallaq, Ainhoa Arina, Nikolai N. Khodarev, Linda Janisch, Paul Chang, Jyoti D. Patel, Gini F. Fleming, John Moroney, Manish R. Sharma, Mark J. Ratain, Thomas F. Gajewski, Ralph R. Weichselbaum, and Steven J. Chmura, The University of Chicago, Chicago, IL; Julia R. White, The Ohio State University, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978468PMC
June 2018

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.

Invest New Drugs 2017 06 3;35(3):298-306. Epub 2017 Jan 3.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0420-1DOI Listing
June 2017

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.

Clin Cancer Res 2015 Nov 21;21(22):5092-9. Epub 2015 Jul 21.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois. Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois. Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-0427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677671PMC
November 2015

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

J Clin Oncol 2014 Aug 23;32(22):2328-34. Epub 2014 Jun 23.

Federico Innocenti, Richard L. Schilsky, Jacqueline Ramírez, Linda Janisch, Samir Undevia, Larry K. House, Soma Das, Kehua Wu, Michelle Turcich, Theodore Karrison, Michael L. Maitland, Ravi Salgia, and Mark J. Ratain, University of Chicago, Chicago; and Robert Marsh, NorthShore University Health System, Evanston, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105486PMC
August 2014

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.

Cancer Chemother Pharmacol 2011 Dec 23;68(6):1629-32. Epub 2011 Aug 23.

Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-011-1727-4
Publisher Site
http://dx.doi.org/10.1007/s00280-011-1727-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259680PMC
December 2011

A phase I study of continuous infusion cilengitide in patients with solid tumors.

Invest New Drugs 2012 Apr 14;30(2):604-10. Epub 2010 Sep 14.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9537-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059335PMC
April 2012

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.

Clin Cancer Res 2009 Feb;15(4):1428-34

Department of Pediatrics, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147153PMC
February 2009

A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.

Cancer Chemother Pharmacol 2004 Dec 2;54(6):553-61. Epub 2004 Sep 2.

Section of Hematology/Oncology, Department of Medicine, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637-1470, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-004-0857-3
Publisher Site
http://dx.doi.org/10.1007/s00280-004-0857-3DOI Listing
December 2004

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Invest New Drugs 2004 Nov;22(4):449-58

Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/B:DRUG.0000036687.26604.8cDOI Listing
November 2004

A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.

Cancer Chemother Pharmacol 2004 Nov 3;54(5):377-84. Epub 2004 Jul 3.

Section of Hematology/Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC 2115, IL 60637-1470, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-004-0841-y
Publisher Site
http://dx.doi.org/10.1007/s00280-004-0841-yDOI Listing
November 2004

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.

Cancer Chemother Pharmacol 2002 Jul 9;50(1):1-5. Epub 2002 May 9.

Department of Medicine, Section of Hematology/Oncology, University of Chicago MC2115, 5841S. Maryland Ave., Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-002-0458-y
Publisher Site
http://dx.doi.org/10.1007/s00280-002-0458-yDOI Listing
July 2002